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ARTICLE
Orofacial Cleft Risk Is Increased with Maternal Smoking
and Specific Detoxification-Gene Variants
Min Shi, Kaare Christensen, Clarice R. Weinberg, Paul Romitti, Lise Bathum, Anthony Lozada,
Richard W. Morris, Michael Lovett, and Jeffrey C. Murray
Maternal smoking is a recognized risk factor for orofacial clefts. Maternal or fetal pharmacogenetic variants are plausible
modulators of this risk. In this work, we studied 5,427 DNA samples, including 1,244 from subjects in Denmark and
Iowa with facial clefting and 4,183 from parents, siblings, or unrelated population controls. We examined 25 single-
nucleotide polymorphisms in 16 genes in pathways for detoxification of components of cigarette smoke, to look for
evidence of gene-environment interactions. For genes identified as related to oral clefting, we studied gene-expression
profiles in fetal development in the relevant tissues and time intervals. Maternal smoking was a significant risk factor
for clefting and showed dosage effects, in both the Danish and Iowan data. Suggestive effects of variants in the fetal
NAT2 and CYP1A1 genes were observed in both the Iowan and the Danish participants. In an expanded case set, NAT2
continued to show significant overtransmission of an allele to the fetus, with a final P value of .00003. There was an
interaction between maternal smoking and fetal inheritance of a GSTT1-null deletion, seen in both the Danish (Pp
) and Iowan ( ) studies, with a Fisher’s combined P value of !.001, which remained significant after correction.03 Pp .002
for multiple comparisons. Gene-expression analysis demonstrated expression of GSTT1 in human embryonic craniofacial
tissues during the relevant developmental interval. This study benefited from two large samples, involving independent
populations, that provided substantial power and a framework for future studies that could identify a susceptible pop-
ulation for preventive health care.
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Clefts of the upper lip and palate are common birth defects
whose etiology includes genes, environment, and their in-
teraction effects. Because they appear to have separate eti-
ologies, affected subjects are categorized as having either
cleft lip with or without cleft palate (CL/P) or as having
cleft palate only (CPO).1 The prevalence (at birth) of oro-
facial clefts (OCs) is related to environmental factors, geo-
graphic origin, and socioeconomic status.2,3 Among the en-
vironmental factors, maternal cigarette smoking is one of
the most widely studied,4–9 with some disparities in results
that may be explained by population differences, sampling
variation, and the variations in inherited pharmacogenetic
susceptibilities to effects of cigarette smoking. Nevertheless,
a recent meta-analysis—of 24 case-control and cohort stud-
ies—of the association between maternal smoking during
pregnancy and offspring OC identified statistically signif-
icant associations between maternal smoking and CL/P
(relative risk ; 95% CI 1.25–1.44) and between[RR]p 1.34
maternal smoking and CPO ( ; 95% CI 1.10–RRp 1.22
1.35).10 Investigations of genetic modifiers remain prelim-
inary, with genes involved in the phases I (CYP1A1 [MIM
108330] and EPHX1 [MIM 132810]) and II (GSTM1 [MIM
138350], GSTT1 [MIM 600436], and NAT2 [MIM 243400])
detoxification pathways of special interest.11–13 To inves-
tigate genes involved in the detoxification or the aryl
hydrocarbon receptor–aryl hydrocarbon receptor nuclear
translocator (AHR-ARNT [MIM 600253 and 126110]) path-
way as cofactors with maternal smoking, we studied 25
allelic variants in 16 genes, using two large population-
based OC-affected groups (Iowa and Denmark). Because
effects of maternal cigarette smoking on embryonic de-
velopment are complex, as is the role of fetal and maternal
genes involved in detoxification, we performed statistical
tests of several scenarios: (1) detoxification of the risk-
relevant component in cigarette smoke is influenced by
fetal genotype, (2) a favorable intrauterine environment
is determined by the genotype of a smoking mother, and
(3) the susceptibility detoxification alleles, either of the
fetus or of the mother, have phenotypic expression only
in the presence of the environmental factors (maternal
smoking) or other susceptibility alleles (gene-environment
or gene-gene interaction effects). We corroborated positive
results with gene-expression data available for human em-
bryonic craniofacial tissues.
Material and Methods
Study Populations
DNA samples used in this study came from Iowa and Denmark,
as shown in table 1. The study was approved by the institutional
review boards in Iowa and Denmark, and written informed con-
sent was obtained from each individual (or the parents of minors)
included in the study.
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Table 1. Study Samples Used
Population Study Design
No. of
Families
No. of
Studied
Parents
No. of
Unaffected
Controls
or Siblings
No. of Subjects with Total
CPO CLCP CLO Anomalya Casesb Samples
DBS Case-control 755 0 485c 68 0 270 755
DCS Case-parent 517 978 664d 101 201 156 70 529e 2,171
Iowa Case-control triad 857 1,637 419c 110 157 103 42 445 2,501
Total 2,129 2,615 1,568 279 358 259 112 1,244 5,427
NOTE.—There were 202 subjects in the DBS who had either CLCP or CLO; the total number of subjects with CLCP and CLO
was 819.
a OCs that occur together with other anomalies, such as heart disease, extremity anomalies, or anomalies associated with
syndromic OC.
b Cleft status is not known for some cases, so the numbers of cleft subphenotype will not add to the total number of cases.
c Unaffected control.
d Unaffected sibling.
e A small proportion of families have multiple affected subjects. We randomly selected one affected child for the analysis.
Danish samples.—The Danish samples are derived from two in-
dependent studies. One set, the Danish case-control (DBS) was
obtained through a 3-year (December 1991 to August 1994) case-
control study of CL/P and CPO in Denmark. Newborn-screening
blood spots were used to extract DNA. The 1st-trimester maternal
exposure information, including cigarette smoking, vitamin in-
take, alcohol use, and medication, was obtained via interview
within a few weeks after birth and from birth records. More detail
is provided in the work of Christensen et al.6 Because of the lim-
itation of sample quantity, only a subset of the markers was tested
on this set of samples. A second set of Danish samples—triads of
an affected individual and parents (DCS), for whom DNA was ex-
tracted from cheek swabs—consisted of affected individuals (born
1981–1990), their parents, and, in some families, the unaffected
sibling(s). These samples were collected between 1995 and 2003,
with no overlap with the DBS samples. Epidemiologic exposure
data on smoking and alcohol and vitamin consumption were
available for the DCS samples.
Iowan population.—Patients with clefts who were born between
1987 and 2001 in Iowa were identified through the Iowa Registry
for Congenital and Inherited Disorders. Control children born
without major anomalies and matched by birth month, year, and
sex were also available; for details, see the work of Romitti et al.14
Most of the families provided complete triads, formed by the
index case or control and both biologic birth parents (as deter-
mined by parent report and consistency with Mendelian trans-
mission, by use of the 25 genotyped SNPs). Data on maternal
cigarette-smoking status were collected by questionnaire, mostly
within 12 mo of the proband’s birth, and were collected for the
3-mo period before conception and for each pregnancy trimester.
Data on paternal smoking were available only for a subset of Iowa
data, and preliminary analysis did not identify a paternal smoking
effect, so it was not included in the analysis. Data on a number
of other epidemiologic variables—such as alcohol and vitamin
intake, medication during pregnancy, race/ethnicity, and educa-
tion level—were also recorded. Selected demographic character-
istics and maternal perinatal exposures are summarized in table
2.
Additional sets of samples were used to further investigate the
apparent overtransmission at the NAT2 590 locus. The samples
include 679 Philippine case triads (with children affected with
OC), 13,000 additional Danish samples from 600 families (con-
sisting of subjects with OC, unaffected sibling, the parents, and,
for some families, grandparents), 375 CEPH samples (phenotype
unknown),15 and 921 control triads from Iowa.
Genotyping Method
The studied candidate genes and alleles were selected on the basis
of enzymatic activities, expression data during fetal development,
and sufficient rare-allele frequencies (15%). Samples were geno-
typed either by kinetic PCR16 or by Taqman assays (Applied Bio-
systems).17 For kinetic PCR, each DNA sample was amplified in
two separate reactions, with allele-specific primers in each reac-
tion, and PCR was done in duplicate. Primer sequences are avail-
able on request.
Taqman SNP genotyping assays were obtained through either
the Assay-on-Demand or the Assay-by-Design service from Ap-
plied Biosystems. Reactions were performed in duplicate, with
use of conditions set forth by the manufacturer. The sequences
of primers and probes from the Assay-by-Design service are avail-
able on request.
We investigated 25 polymorphisms in 16 genes; information
on genes and markers is summarized in table 3, with complete
data listed in table 4. All genotyped families were checked for
consistency with Mendelian inheritance, and each gene-SNP com-
bination was checked for Hardy-Weinberg equilibrium. Allele fre-
quencies were calculated separately for mothers, fathers, and chil-
dren and were stratified by population and OC status (see table
5 for details).
Embryonic Gene Expression
Embryonic-expression profiles of the detoxification genes used in
this study were investigated to confirm that the genes were ex-
pressed in the relevant tissue during the relevant interval of em-
bryonic development. One source of expression data is the CO-
GENE (Craniofacial and Oral Gene Expression Network) Project,
which investigates human gene-expression changes that occur
during early stages of development, with a focus on craniofacial
regions. Normal-appearing human embryos from RU-486–in-
duced abortions—that were free of autosomal trisomies and for
which no parental epidemiologic data were available—were used
to generate RNA for micoarray analysis. Affymetrix microarray
analysis was performed on microdissected, normal human cran-
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Table 2. Selected Maternal Characteristics
Characteristics
Iowa DBS DCS
Case
(np 445)
Control
(np 421)
Case
(np 270)
Control
(np 485)
Case
(np 663)
Controla
(np 529)
Age (years):
Data missing (N) 69 7 0 0 17 9
!21 (%) 10.9 9.9 4.8 4.3 5.6 2.9
21–30 (%) 62.4 60.1 63.7 67 69.6 67.6
130 (%) 26.7 30 31.5 28.7 26.8 27.5
Ethnicity (% non-Hispanic white) 96.8 97.3 100 100 100 100
Education:
Data missing (N) 72 8
High school degree or less (%) 73.2 52.5
Some college (%) 19 25.7
Bachelor’s degree or higher (%) 7.8 21.8
Smoking during pregnancy:
Data missing (N) 66 5 0 0 13 11
Yes (%) 27.2 20 39.6 31.8 34.7 30.8
No (%) 72.8 80 60.4 68.2 65.3 69.2
Multivitamin intake during pregnancy:
Data missing (N) 118 24 4 2 87 104
Yes (%) 47.1 39.5 76.7 79.7 76.7 79.6
No (%) 52.9 60.5 23.3 20.3 23.3 20.4
Alcohol intake during pregnancy:
Data missing (N) 142 52 3 13 27 39
Yes (%) 74.3 62.3 62.2 68 36.7 37.2
No (%) 25.7 37.7 37.8 32 63.3 62.8
NOTE.—Percentages are based on the total nonmissing data.
a Unaffected sibling.
iofacial structures of 25 target tissues/stages to construct fetal
gene-expression profiles.18
Statistical Analysis
Statistical analyses were performed separately on samples from
Iowa and Denmark, and P values from these two sources were
combined using Fisher’s method, as described in the “Multiple-
Comparison Considerations” section. We also performed analysis
on the basis of aggregated data, to improve estimation of RRs, if
the estimates were compatible in the separate analysis. Since there
were only a few families ( ) with multiple affected offspring,np 12
one affected child was randomly chosen from such families to
be included in the analysis. The data were analyzed under two
statistical frameworks: a log-linear model (for case-parents triads)
and logistic regression analysis (for case-control comparisons).
Given that the outcome under study is rare, the RR parameters
estimated under the former are equivalent to the odds ratio (OR)
parameters estimated under the latter. When using the log-linear
model in the analysis, we first used a 2-df test, which places no
assumptions on the underlying genetic model (see the “Log-Lin-
ear Framework” section below for a detailed description). We then
fitted the data in a log-additive model when a significant result
was observed.
Multiple-Comparison Considerations
Interactions between genetic and environmental factors are sta-
tistically difficult to study; they are second-order effects, and
many different combinations must be considered. Therefore, the
present analysis faced a multiple-comparison issue. One can sim-
ply multiply the P values by the number of tests performed, in
a full Bonferroni correction, but this method has rightly been
described as “punitively conservative.”19(p505) Here is our approach.
We consider that there are three levels of analysis performed here.
Our primary interest is to identify interactions between genetic
variants—in either the mother or the fetus—and the exposure:
maternal smoking. For our 25 SNPs, this implies that we must
include 50 separate tests in our formal hypothesis–testing frame-
work. There are also two phenotype categories (CPO and CL/P)
and two populations (Iowan and Danish). For the overall formal-
testing framework, we combined the phenotypes and then also
combined the P values for the two populations, using Fisher’s
method.20 We considered an interaction to be significant within
this framework if the P value is !.05/50—that is, 0.001. Another
level of analysis has to do with the main effects for these factors,
such as smoking, which are already known or strongly suspected
to be related to risk or to the metabolism of xenobiotics. We
provide an analysis of these, for improved estimation of their
RRs. A third level should be considered exploratory, rather than
providing formal-hypothesis tests, and that exploratory category
includes gene-by-gene interactions, differences between the Dan-
ish and Iowan populations, and differences between the two sub-
phenotypes. For the second and third sets of analyses, the P values
should be taken as an index of strength of evidence rather than
as providing formal-hypothesis tests.
Log-Linear Framework
Major gene effects.—We used the log-linear approach to study
the effects of fetal and maternal genotypes21,22 in family-based
analyses. The expectation-maximization algorithm was applied,
for full use of the families with a missing parental genotype.23
The log-linear approach tests fetal genetic effects by comparing
the distribution of the case genotype after stratification by pa-
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Table 3. Summary of Marker Information
Gene Name and SNP or Deletion
Gene/SNP
Designation
Allele
Frequencya
(%) Functional Effects of Variantsb
Aryl hydrocarbon receptor:
G1721A AHR_snp1 7 Higher inducibility for CYP1A1
ArG AHR_snp2 31 Unknown
Cytochrome P450 1A1:
T3801C CYP1A1c 7 Stabler mRNA, higher activity
Cytochrome P450 1A2:
164CrA in intron 1 CYP1A2c 32 Lower activity
Cytochrome P450 1B1:
Val432Leu CYP1B1_snp1 49 Lower activity
Asn453Ser CYP1B1_snp2 15 Unknown
Cytochrome P450 2E1:
GrA CYP2E1 21 Unknown
Microsomal epoxide hydrolase:
Y113H EPHX1_snp1c 32 Higher activity
His139Arg EPHX1_snp2 22 Higher activity
Glutathione transferases alpha-4:
GrC GSTA4_snp1 41 Unknown
TrC GSTA4_snp2 27 Unknown
Glutathione transferases mu-1:
Null deletion GSTM1_nullc 56 Loss of function
CrG GSTM1_snp1 37 Unknown
Glutathione transferases mu-3:
GrA GSTM3 37 Unknown
Glutathione transferases pi-1:
A313G GSTP1_snp1c 38 Lower activity
C341T GSTP1_snp2 10 Unknown
GrT GSTP1_snp3 46 Unknown
Glutathione transferases theta-1:
Null deletion GSTT1_nullc 18 Loss of function
Hypoxia-induced factor-1 alpha subunit:
ArC HIF1A 25 Unknown
N-acetyltransferases (NATs) 2:
C481T NAT2_snp1c 41 Unknown
G590A NAT2_snp2c 33 Lower activity
NAD(P)H: quinone oxidoreductase:
C609 T NQO1c 17 Loss of function
Sulfotransferases 1A1:
R213H SULT1A1 38 Lower activity
UDP-glucuronosyltransferases 1A7:
T387G, C391A, and G392A UGT1A7_snp1 63 Unknown
T662C UGT1A7_snp2 36 Unknown
NOTE.—The SNP designations are used in other tables as references to markers.
a Allele frequencies were based on Iowan control samples.
b Change in enzymatic activities of the variant allele (the second allele listed in SNP column).
c Only these markers were genotyped on the DBS samples.
Table 4. Detailed Marker Information
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
rental genotypes with the expected distribution under Mendelian
inheritance. The unit of analysis is the triad, consisting of an
affected offspring and the two parents. Tests of maternally me-
diated genetic effects—that is, effects on the fetus that are due
to effects of the maternal genotype on the maternal phenotype
during pregnancy—are based on the symmetry assumption of
allele counts between the mothers and the fathers in the source
population, as defined by Schaid and Sommer.24 The log-linear
approach provides likelihood-ratio tests (LRTs) of the genetic ef-
fects as well as maximum-likelihood estimators of the genetic
RRs for both offspring-mediated and mother-mediated genetic
effects.21 This approach has the advantage of allowing for differ-
ent RRs that correspond to carrying one and carrying two copies
of a susceptibility-related allele, relative to no copies. Simulation
studies have shown the log-linear approach to be more powerful
under a dominant or a recessive disease model than with another
transmission/disequilibrium–based test.25 A limitation of the triad
approach is that, unlike the case-control design, it does not pro-
vide a way to detect effects of exposures on risk, although one
can assess multiplicative interactions between exposure and
genotypes.26
Effects of gene and maternal-smoking interaction.—For the Iowan
samples, smoking status during the critical period between 3 mo
before and 3 mo after conception served as the indicator variable
for smoking in testing gene–maternal-smoking interaction ef-
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Table 5. Allele Frequencies
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 1. ORs of maternal cigarette smoking in different popu-
lation and different phenotypic subgroups. All Pheno p all sub-
jects with OC (with or without other anomalies); No Anom p
subjects with OC and without other associated anomalies.
fects. For the Danish sample, for which the smoking exposure
before conception was not ascertained directly, smoking status
in the 1st trimester was used. For the triad-based analyses, we
applied an extension of the log-linear approach26 in analyzing
interaction effects between maternal genotypes and maternal cig-
arette smoking. We applied the polytomous logistic-regression
approach,27 originally developed for testing linkage and associ-
ation in relation to quantitative traits (QTs), in analysis of fetal-
gene and maternal-smoking interaction effects, by substituting
the maternal-smoking status for the QT. This approach compares
the allele transmission to affected offspring for triads with smok-
ing versus triads with nonsmoking mothers. A multiplicative in-
teraction would be evidenced by a difference between the two
transmission patterns.
Gene-gene interaction.—The log-linear framework for testing
gene-environment interaction was adapted for testing gene-
gene interaction by treating one genetic factor as the environ-
mental factor and applying the method described in the “Effects
of gene and maternal-smoking interaction” section. To reduce
the degrees of freedom of the test statistic by using a more par-
simonious alternative model formulation, we assumed a domi-
nant or a recessive effect of the genetic factor. The test does re-
quire that the “exposure” and the inherited genotype be inde-
pendent, conditional on the parental genotypes and hence could
be validly used only for unlinked loci. We included in this analysis
two genes, IRF6 (MIM 607199)28 and MSX1 (MIM 142983),29 that
have elsewhere shown association with OC and on which geno-
type data were available for the samples used in the present study.
Heterogeneity in genetic RR.—When heterogeneity in genetic RRs
exists between different populations, it is not appropriate to com-
bine the data for analysis. We used the log-linear framework for
testing gene-exposure interaction to test for the heterogeneity in
genetic RRs across studies by treating population group as the
exposure variable. When there was no evidence of heterogeneity,
we tested fetal or maternal genetic effects, using the combined
data.
Logistic-Regression Framework
GSTT1- and GSTM1-null deletion polymorphisms present a chal-
lenge, in that the genotyping method we applied can detect only
the presence or absence of the normal allele, not the exact copy
number (1 vs. 2 alleles). Logistic-regression analyses were applied
in estimation of genetic, maternal, and gene-smoking interaction
effects of these two polymorphisms for all the markers in case-
control comparisons. For triad samples, we adjusted for parental
genotypes, if available, in testing for child genetic effects or child
gene–maternal smoking interaction.
In analysis of the combined data from different studies, we
included a variable indicating the specific substudy, together
with interactions between that indicator and the other covariates,
whereby the parameters of the tested effects were constrained to
be the same across substudies and all other parameters were free
to vary. We fit logistic models both with and without adjustment
of other epidemiologic factors, such as vitamin intake and alcohol
use.30 Data collected from the DBS samples were analyzed using
logistic regression in similar ways.
We applied the Cochran-Armitage trend test30 to assess the dos-
age effect of cigarette smoking (using smoking amounts as con-
secutive integers). We also calculated the attributable fraction for
the interaction between GSTT1 and maternal smoking. Popula-
tion attributable fraction for interaction on a multiplicative scale
provides an estimate of the reduction in OC occurrence that
would result from eliminating the interaction.31
Results
Smoking Effects
We observed an increased risk of CL/P in the offspring of
smoking mothers in both the Danish ( ; 95% CIORp 1.53
1.08–2.16) and Iowan ( ; 95% CI 1.06–2.50) case-ORp 1.62
control substudies, after adjusting for maternal perinatal
multivitamin and alcohol use (fig. 1). To quantify tobacco
use, we divided maternal smoking into four groups for
analysis (in the Danish samples: group 1, 0/d; group 2, 1–
9/d; group 3, 10–19/d; group 4,  20/d; in the Iowan
samples: group 1, 0/d; group 2, 1–4/d; group 3, 5–15/d;
group 4, 115/d). Mothers who smoked 10–19 cigarettes/d
in the DBS samples and those who smoked 15 cigarettes/
d in the Iowan samples had the highest risk of OC (table
6). We saw ORs of 1.33 (95% CI 1.09–1.62) for CL/P and
1.29 (95% CI 0.97–1.73) for CPO in the smoking mothers
in the unified data set (Iowa and Denmark), after adjust-
ment for sample origins and maternal perinatal multivi-
tamin use and alcohol intake (fig. 1). It should be noted
that, although the point estimate of OR is higher for the
10–19/d group than for the 120/d group in the Danish
samples, this most likely results from the small sample
size of the 120/d group, as indicated by the observation
that the 95% CI of OR for the 10–19/d groups is contained
within that for the 120/d group. Using the Cochran-Ar-
mitage trend test, we also identified dosage effect of ma-
ternal smoking for both populations (data not shown).
Maternal perinatal multivitamin or alcohol use did not
show significant association with OC, after adjustment for
maternal smoking (data not shown).
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Table 6. Effects of Smoking
by Cigarettes per Day
Phenotype,
Population,
and No. of
Daily Cigarettes OR 95% CI
All OCs:
DBS:
1–9 1.12 .65–1.92
10–19 1.55 1.06–2.25
20 .93 .42–2.06
Iowa:
1–4 .84 .42–1.70
5–14 2.17 1.17–4.03
15 2.17 1.15–4.07
CL/P:
Denmark:
1–9 1.14 .62–2.08
DBS:
10–19 1.71 1.14–2.56
20 1.16 .51–2.64
Iowa:
1–4 .93 .42–2.07
5–14 2.24 1.11–4.50
15 2.78 1.42–5.44
CPO:
Denmark:
1–9 1.03 .42–2.57
DBS:
10–19 1.17 .61–2.23
20 .35 .05–2.67
Iowa:
1–4 .91 .30–2.75
5–14 2.52 1.09–5.81
15 1.58 .59–4.21
Table 7. Transmission/Disequilibrium Tests of NAT2 G590A
Marker
Sample
No. of Subjects
with
Transmission
No. of
Triads
(1,1,1)a x2 PG A
Case set 1b 278 204 58 9.2 .002
Control set 1b 313 248 62 6.2 .013
Case set 2c 357 275 78 8.5 .003
Control set 2d 450 434 111 .2 .630
All casese 635 479 136 17.6 53# 10
All controls 763 682 173 3.7 .056
a Triad (1,1,1) represents a triad in which mother, father, and child
are all heterozygous (GA).
b Set 1 consists of the Iowa and DCS samples that are used in testing
other markers.
c Case set 2 consists of the Philippine triad samples and an additional
set of Danish familial samples.
d Control set 2 consists of the CEPH samples, affected siblings in the
second set of Danish familial samples, and white control triad samples.
e “All cases” and “All controls” represent the combined data set of
set 1 and set 2.
Genetic Effects
We tested a variety of genetic effects, including fetal geno-
type and maternal genotype, maternal smoking by gene
(fetal or maternal gene) interaction, and gene-by-gene in-
teraction effects. Tables A1–A7 represent a subset of these
results that are at least suggestive of a possible effect (P
). The P values listed in tables 7 and A1–A7 have not.03
been adjusted for multiple comparisons. In table A8, we
summarized the markers with P values !.05 for individual
tests in the three studied sample sets and for different
effect types (fetal genotype, maternal genotype, fetal geno-
type and smoking interaction, and maternal genotype and
smoking interaction).
Maternal effects.—Tests on maternal effects, either ma-
ternal genotype effects or interaction effects between ma-
ternal genotype and maternal smoking, identified cer-
tain genes that may play a role through maternal geno-
types, including EPHX1, GSTP1 (MIM 134660), NAT2, and
UGT1A7 (MIM 606432) (tables A1 and A2).
Fetal effects.—Tests specific for genetic effects of the off-
spring genotype identified suggestive effects of variants
in the CYP1A1, CYP1A2 (MIM 124060), CYP1B1 (MIM
601771), GSTA4 (MIM 605450), GSTP1, and NAT2 genes
(table A3). Whereas we saw most of the apparent effects
in either the Iowan or the Danish samples but not in both,
for variants in CYP1A1 and NAT2, the overall results sug-
gest an effect in both populations. The risk of OC was
estimated to decrease by 20% (40%) and 30% (50%) re-
spectively, when a child carries 1 copy (2 copies) of the
variant allele of CYP1A1 or NAT2.
Fetal effects: GSTT1.—Several genes—including EPHX1,
GSTA4, GSTP1, UGT1A7 (table A4), and GSTT1 (tables 8,
A5, and A6)—showed significant interaction effects be-
tween the fetal genotype and maternal smoking, with the
effect of GSTT1 remaining significant after correction for
multiple comparisons. Similar to results for fetal genetic
effects, the apparent interaction effects were usually ob-
servable in only one population. However, interaction ef-
fects between the GSTT1-null genotype and maternal
smoking were detected in the Iowan ( ) and DBSPp .003
samples ( ) (table A5), with a Fisher’s combined PPp .03
value of .0009, which remained significant after Bonfer-
roni correction for 50 tests. An estimated increase in risk
of CL/P was observed when the child carried the null ge-
notype and the mother smoked. The interaction effects
were stronger in the CPO subgroup in both populations,
and the combined data showed even more-significant re-
sults ( ) (table A5). ORs of maternal smoking forPp .001
OC were most elevated in the GSTT1-null fetuses whose
mothers smoked 10–19 cigarettes/d for the Danish sam-
ples ( ; 95% CI 1.4–12.4) and in the GSTT1-nullORp 4.2
genotyped fetuses whose mothers smoked 115 cigarettes/
d for the Iowan samples ( ; 95% CI 2.1–141.4)ORp 17.1
(table 8). The Cochran-Armitage trend tests detected sig-
nificant dosage effects in the GSTT1-null genotyped sub-
jects with OC in both the Danish samples and the Iowan
samples (table 8). Table A6 shows the table for study-2# 4
ing gene-environment interaction effects suggested by
Botto et al.32
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Table 8. ORs by Fetal GSTT1 Genotype and Maternal
Smoking Categories
Population,
GSTT1 Genotype,
and No. of
Daily Cigarettes Case Control OR 95% CI
DBS:
/ or /a:
0 113 223 Reference
1–9 34 61 1.10 .68–1.77
10–19 54 82 1.30 .86–1.96
20 8 18 .88 .37–2.08
/b:
0 18 44 Reference
1–9 8 9 2.17 .72–6.52
10–19 12 7 4.19 1.42–12.36
20 3 3 2.44 .45–13.27
Iowa:
/ or /c:
0 172 180 Reference
1–4 8 15 0.56 .23–1.35
5–14 22 14 1.64 .82–3.32
15 24 14 1.79 .90–3.58
/d:
0 30 57 Reference
1–4 3 3 1.90 .36–10
5–14 6 2 5.70 1.83–29.99
15 9 1 17.10 2.07–141.4
a Cochran-Armitage trend test ; .Zp .83 Pp .409
b Cochran-Armitage trend test ; .Zp 2.56 Pp .011
c Cochran-Armitage trend test ; .Zp 1.85 Pp .064
d Cochran-Armitage trend test ; .Zp 3.87 Pp .0001
With the assumption of a smoking prevalence of 25%
in pregnant women and a GSTT1-deletion prevalence of
15%, the attributable fraction of the interaction on a mul-
tiplicative scale between GSTT1 deletion and maternal
smoking is calculated to be 6%.31 The parameter estimates
show that the GSTT1-null genotype confers a considerable
risk when combined with smoking (double the risk) and
no risk (maybe even a protective effect) if the mothers do
not smoke.
Fetal effects: NAT2.—Although fetal genetic effects were
not part of the formal hypothesis–testing framework, the
result of the NAT2 G590A marker is of special interest. The
NAT2 G590A SNP showed association in both the Iowan
( ) and the Danish samples ( ). The test ofPp .04 Pp .01
heterogeneity in genetic RRs between the Iowan and Dan-
ish samples was not significant and supported the pooling
of genotype data for analysis. The NAT2 G590A marker
also demonstrated significant transmission distortion in
the initial studied control samples (see the “Danish sam-
ples” and “Iowan population” sections) as well, although
to a less extreme degree ( ) (last line of table A3).Pp .021
To further evaluate the apparent overtransmission, we in-
vestigated additional case and control samples. The ov-
ertransmission at the NAT2 590 locus continued to be ob-
served in the case samples but was no longer observed in
the control samples (table 7).
Gene-Gene Interaction Effects
Preliminary analyses also suggested gene-gene interactions
between several pairs of genes (table A7).
Expression Data
Expression profiles of the detoxification genes used in this
study were investigated using COGENE expression data,
as summarized in figure 2. Over 97% of human genes show
expression below the level shown by GSTT1 in this study.
GSTT1 demonstrated an elevated expression in the human
craniofacial embryonic tissues, and its expression corre-
lates with that of fibroblast growth factor receptors 1 and
2 (FGFR1 [MIM 136350] and FGFR2 [MIM 176943])33 (data
not shown), genes that are known to be involved in cran-
iofacial development. Several genes involved in detoxifi-
cation of exogenous exposures are also thought to play
a role in metabolism of endogenous morphogens in the
fetus, to regulate development, so the role of these gene
products may be different in the mother and the fetus.34
Discussion
We report here a comprehensive study of effects of poly-
morphisms in genes involved in detoxification pathways
and the interaction effects between these genetic variants
and maternal cigarette smoking on a common birth de-
fect: OC. The study benefited from large sample sizes in
both Denmark and Iowa, which allowed comparisons and
replications.
Maternal cigarette smoking adversely affects the health
of both the mother and child, with increased risks of low
birth weight, premature rupture of membranes, placenta
previa, neonatal mortality, and stillbirth.35 It also causes
increased health-care expenditures. The estimated smok-
ing-attributable neonatal expenditures were $366 million,
or $704 per maternal smoker, in the United States in 1996.36
In the present study, we identified an increased risk of
OC in the offspring of smoking mothers in Denmark and
Iowa. This finding lends further support for advocation of
smoking-cessation programs.
Studies of gene-environment interaction effects have
become increasingly important for complex traits such
as clefting, whose etiology probably involves both genes
and environmental factors. Gene-knockout mice that lack
expression of AHR and certain CYPs (CYP1A1, CYP1A2,
CYP1B1, CYP2E1 [MIM 124040]), EPHX1, GSTP1, GSTA4,
and NQO1 [MIM 125860]) and are raised in a clean en-
vironment have no deleterious phenotypes, indicating
that these genes have no direct roles in murine embryonic
development. However, the knockout mice do have dif-
ferent response profiles when challenged with toxicants
and carcinogens.37–39 This accentuates the importance of
studying gene-environment interactions. Of the detoxi-
fication genes showing suggestive gene-environment in-
teraction effects in this study, EPHX1, GSTA4, and GSTP1
were reported to be expressed in developing embryos, and
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Figure 2. COGENE expression summary of detoxification genes. For evaluation of the expression level, the numerical values were
assigned to the results of chip analysis with p (present)p2, m (marginal)p1, and a (absent)p0, and expression scores were calculated
from the average of the replicate experiments. The column headings indicate the developmental stage and sample tissue.
the COGENE data showed elevated expression of GSTP1,
GSTA4, GSTT1, and HIF1A (MIM 603348) at the critical
regions and time during craniofacial development. In ad-
dition, an association was observed between the fetal ge-
notype in GSTA4 and clefting (table A4), although it was
seen in the Danish and not in the Iowan data. Such dif-
ferences could suggest that the variant we studied is a
marker in linkage disequilibrium with a clefting locus in
the Danish but not in the Iowan population.
Preferential transmission of the common allele of NAT2
G590A was observed in samples from the Iowan and Dan-
ish populations (table 7). However, this preferential trans-
mission was also observed, albeit with less transmission
distortion, in unaffected controls. Accordingly, a supple-
mental study was performed using additional control sam-
ples (see the “Danish samples” and “Iowan population”
sections). No preferential transmission was seen in the
second (larger) set of controls ( ), and the apparentPp .63
transmission distortion was of only borderline significance
for all controls combined ( ). Several possible ex-Pp .056
planations can be proposed, including sampling variation,
systematic genotyping mistakes, actual effects of the var-
iant allele on fetal survival, and segregation distortion.
Consistency in genotypes of 1300 samples, through use
of kinetic PCR and Taqman assays designed for this marker
and DNA sequencing of 90 samples, argues against geno-
typing errors. Zo¨llner et al. reported evidence of extensive
transmission ratio distortion in several regions in the hu-
man genome, one of which was located on chromosome
8, coinciding with the chromosomal location of NAT2.40
In the final, complete data set for the NAT2 G590A marker,
we observed overtransmission in the OC samples but not
in the controls, which argues for an etiologic role of this
variant. One other study9 has investigated the associa-
tion between variants in the fetal NAT2 gene—including
G590A—and clefting, and the researchers did not detect
a significant association with the NAT2 G590A marker.
That study, however, was performed using a case-control
study design, which could be subject to bias due to genetic
population stratification. Further study of the NAT2 G590A
locus is required to fully understand the observed over-
transmission. NAT2 is a member of the N-acetyltransfer-
ases family, which comprises two protein-encoding genes
(NAT1 and NAT2) and a pseudogene. NAT2 catalyzes the
N-acetylation of carcinogens and other xenobiotics such
as arylamines, hydrazines, and hydrazides.41 NAT2 G590A
has reduced catalytic activity and protein stability in vi-
tro,42 and, whereas the COGENE data did not identify
craniofacial embryonic expression for NAT2, the homo-
log, NAT1, is expressed in mouse fetal liver.43
GSTT1 is widely studied in the investigations of envi-
ronmental effects, and the null genotype has been asso-
ciated with increased chromosome aberrations and cer-
tain cancers.44 Using a case-control design, Van Rooij et
al. reported increased risk of OC when mothers carry the
GSTT1-null genotype and smoke cigarettes or when both
mothers and infants carry the null genotype and mothers
smoke.12 We saw increases in risk of OC associated with
the GSTT1-null genotypes in the fetus in the Iowan and
DBS components of our study and similar estimated ORs.
In a population-based case-control study, Lammer et al.
identified a doubling of risk of cleft lip only (CLO) for fe-
tuses who had both a null genotype for GSTT1 and a mother
who smoked, and there was a nearly sixfold increased risk
of CL for fetuses with a combination of a mother who
smoked and an absence of GSTM1 and GSTT1.45 The CO-
GENE data show that GSTT1 is highly expressed in de-
veloping fetal craniofacial structures, which suggests that
its absence in null-genotype individuals could contribute
to abnormalities. One possibility is that GSTT1 is present
in the embryo to metabolize endogenous morphogens, as
has been suggested for the cytochrome P450 pathway
genes and retinoic acid.34 Absence of GSTT1 in the pres-
ence of xenobiotics present in cigarette smoke might result
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in disruptions of normal signaling. These results are con-
sistent with our finding that fetal GSTT1-null genotype
combined with maternal smoking increases the risk of OC.
In the present study, the estimated RR for the GSTT1-null
mothers who smoked during pregnancy was 2.38, whereas
that for the GSTT1-null mothers who did not smoke was
0.67.
We used a Bonferroni correction to correct our gene-
environment interaction analysis for multiple-testing, and
we observed significant association for interactive effects
between fetal GSTT1-null genotype and maternal smok-
ing, after the correction. Nevertheless, it is worth noting
that, for such complex diseases as OC, multiple genetic
and environmental factors are involved in the etiology,
each contributing, at best, a moderate effect. It is likely
that true-positive signals will be missed with strict adher-
ence to the multiple-testing correction rule. Rather, the
significant results identified in the present study provide
preliminary evidence for their involvement, and future
confirmation studies are required.
The specific SNPs selected for analysis may not be func-
tionally important variants but may serve as markers in
linkage disequilibrium with a functionally relevant haplo-
type. As markers, some SNPs may be more informative in
some populations than in others, and this could explain
some of the discrepancies in our analyses between results
for the Iowan and the Danish populations. One should
note that, even with a power of 0.8 at the causal SNP, the
chance of replication of association is 0.64 in two inde-
pendent samples and 0.51 in three independent samples.
In summary, our investigations of the effects of detox-
ification genes and maternal smoking on the etiology of
clefting are the most comprehensive to date, in terms of
the number of genes studied and the number of samples
included. Results supporting a role for genetic, maternal,
gene-smoking interactive, and gene-gene interaction ef-
fects were identified, which provide a valuable resource
for future investigations. The demonstration of an inter-
action between maternal smoking and GSTT1 variants may
make it possible for risk counselors to identify couples for
whom behavior modification may help substantially re-
duce OC risk.
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Appendix A
Table A1. Maternal Effects
Gene and
Phenotype
Denmark Iowa Combined Data
General-Effect Model
Log-Additive
Model General-Effect Model
Log-Additive
Model General-Effect Model
Log-Additive
Model
RR1 RR2
LRT
(P) R_A
LRT
(P) RR1 RR2
LRT
(P) R_A
LRT
(P) RR1 RR2
LRT
(P) R_A
LRT
(P)
EPHX1_snp1:
CL/P .65 1.43 .003 .91 .43 1.07 .78 .65 .95 .70 .78 1.09 .09 .93 .40
CPO 2.82 .86 !.001 1.34 .10 .96 .64 .65 .86 .47 1.69 .76 .01 1.11 .44
GSTP1_snp3:
CPO .81 .32 .002 .57 .001 1.18 1.88 .25 1.34 .11 THRRa
GSTP1_snp1:
CPO 1.18 .42 .02 .75 .08 1.33 2.13 .27 1.42 .11 1.24 .77 .25 .95 .69
NAT2_snp1:
Allb 1.37 1.40 .06 1.20 .03 .78 .77 .28 .85 .16 1.06 1.12 .69 1.06 .39
No anomaliesc 1.26 1.51 .08 1.23 .02 .77 .79 .27 .85 .18 1.01 1.18 .47 1.07 .32
CLO 1.28 1.22 .61 1.12 .443 .41 .33 .03 .51 .02 THRRa
CPO 1.95 2.56 .01 1.64 .004 1.16 .71 .46 .92 .67 1.52 1.53 .09 1.28 .05
UGT1A7_snp2:
Allb .84 .68 .16 .83 .051 1.14 .78 .193 .89 .306 .96 .7 .047 .86 .034
CPO .82 .42 .08 .69 .037 1.61 .84 .13 .91 .665 1.04 .55 .048 .79 .076
NOTE.—RR1 is the genetic RR when the mother carries one copy of the variant allele; RR2 is that when the mother carries two copies of the
variant alleles; R_A is the RR when the mother carries one copy of the variant allele, assumed to be a log additive model, a model in which the
RR of carrying two copies of the variant alleles is the square of that of carrying one copy.
a For test of heterogeneity in RR (THRR), .P ! .05
b Includes data from all subjects with nonsyndromic OC.
c Includes data from subjects without other minor anomalies.
Table A2. Maternal Genotype and Maternal Smoking
Interactive Effects
Gene and
Phenotype
Denmark Iowa
PaI1 I2
LRT
(P) I1 I2
LRT
(P)
NAT2_snp2:
Allb 2.03 .87 .03 .84 .63 .80 .110
No Anomaliesc 2.48 .79 .006 .79 .54 .68
UGT1A7_snp1:
Allb 1.73 .68 .01 2.58 5.58 .01 .001e
No anomaliesc 1.71 .71 .04 2.37 5.37 .01
CLO .71 .36 .29 10.5 29.8 .024
CPO 7.76 1.51 .03 … … …
NOTE.—I1 is the estimated interaction effect of one maternal copy of
the variant allele together with maternal smoking; I2 is the estimated
interaction effect of two maternal copies of the variant allele together
with maternal smoking.
a For formal-hypothesis testing, we used Fisher’s method to combine
P values that were based on data from all OC cases in the Danish and
Iowan populations.
b Includes data from all subjects with nonsyndromic OC.
c Includes data from subjects without other minor anomalies.
d Estimates for interaction effects were different in the Danish and
Iowan populations.
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Table A3. Effects of Offspring Genotypes
Gene/SNP and
Phenotype
Denmark Iowa Combined
RR1 RR2
LRT
with
2 df
(P) R_A
Additive
Model
LRT
with
1 df
(P) RR1 RR2
LRT
with
2 df
(P) R_A
Additive
Model
LRT
with
1 df
(P) RR1 RR2
LRT
with
2 df
(P) R_A
Additive
Model
LRT
with
1 df
(P)
CYP1B1_snp1:
Alla 1.2 1.2 .53 1.1 .45 .7 .8 .03 1.0 .71 1.0 1.0 .54 1.0 .71
CL/P 1.2 1.2 .60 1.1 .42 .6 .7 .05 .8 .22 .9 1.0 .72 1.0 1.00
CPO 1.0 .9 .93 .9 .70 1.3 2.5 .04 1.7 .02 1.1 1.4 .37 1.2 .23
CYP1A1:
Alla .6 .8 .03 .7 .01 .7 1.1 .20 .8 .17 .7 1.0 .006 .7 .007
No anomaliesb .7 1.0 .11 .7 .068 .6 .8 .09 .7 .05 .7 .9 .01 .7 .008
CYP1A2:
CPO 2.1 .8 .005 1.5 .05 1.4 1.2 .58 1.3 .41 1.7 1.3 .01 1.4 .03
GSTA4_snp2:
No anomaliesb .7 .8 .007 .7 .01 1.0 1.4 .61 1.1 .61 .8 1.0 .04 .9 .11
CLO .6 1.7 .005 .9 .40 .6 .5 .12 .6 .06 .6 1.2 .001 .8 .07
GSTM1_snp1:
CPO 1.3 3.5 .02 1.7 .01 1.1 1.1 .98 1.1 .82 THRRc
GSTP1_snp3:
Alla 1.1 1.0 .47 1.0 .86 1.2 .6 .01 .9 .19 THRRc
CL/P 1.1 1.1 .60 1.0 .70 1.1 .5 .01 .8 .16 THRRc
NAT2_snp2:
Alla .8 .6 .04 .8 .01 .8 .6 .12 .8 .04 .8 .6 .006 .8 .001
No anomaliesb .8 .6 .07 .8 .02 .8 .6 .20 .8 .07 .8 .6 .01 .8 .003
CL/P .8 .4 .01 .7 .01 .9 .6 .43 .8 .24 .8 .5 .007 .7 .002
Control .7 .8 .01 .8 .02 1.0 .8 .67 .9 .43 .8 .8 .03 .8 .02
NOTE.—RR1 is the genetic RR when the child carries one copy of the variant allele; RR2 is that when the child carries two copies of the variant alleles;
R_A is the RR when the child carries one copy of the variant allele, assumed to be a log additive model, a model in which the RR of carrying two copies
of the variant alleles is the square of that of carrying one copy.
a Includes data from all subjects with nonsyndromic OC.
b Includes data from subjects without other minor anomalies.
c For test of heterogeneity in RR (THRR), .P ! .05
Table A4. Interactions between Fetal Genotype and Maternal Smoking
Gene and
Phenotype
Danish Iowa
Pa
C#E 1
(I1)
C#E 2
(I2)
C#E LRT
(P)
CxE 1
(I1)
CxE 2
(I2)
C#E LRT
(P)
EPHX1_snp1:
Allb .82 .68 .62 .92 16.6 .004 .017
No anomaliesc .94 .77 .87 .96 14.0 .01
GSTA4_snp1:
CPO .20 1.78 .01 1.37 1.72 .78
GSTA4_snp2:
CPO .23 3.63 .01 .78 2.60 .65
GSTP1_snp1:
CL/P .50 1.94 .02 1.26 .86 .89
HIF1A:
Allb .82 .37 .20 3.02 1.13 .02 .027
No anomaliesc .82 .39 .28 2.89 1.19 .04
UG1A7_snp1:
Allb 2.30 1.44 .08 2.96 .53 .02 .014
No anomaliesc 2.14 1.63 .12 3.34 .53 .01
CPO 13.5 1.19 .02 4.94 .70 .25
NOTE.—I1 is the estimated interaction effect of one fetal copy of the variant allele
together with maternal smoking; I2 is the estimated interaction effect of two fetal copies
of the variant allele together with maternal smoking.
a For formal hypothesis testing, we used Fisher’s method to combine P values that were
based on data from all OC cases in the Danish and Iowan populations.
b Includes data from all subjects with nonsyndromic OC.
c Includes data from subjects without other minor anomalies.
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Table A5. Interaction between Fetal GSTT1 Genotypes and Maternal Smoking
Population and
Phenotype
RR
(unexpa)
95% CI
of RR–
RR
(expb)
95% CI
of RR–
RR
(interactionc)
95% CI
of RR x2 P
Adjusted
Pd
DBS:
Alle .84 .48–1.46 2.34 1.12–4.91 2.79 1.11–7.01 4.9 .03f .03
CPO .87 .35–2.19 4.22 1.39–12.85 4.83 1.14–20.43 4.5 .03 .03
CL/P .83 .44–1.55 1.97 .89–4.38 2.38 .86–6.55 2.8 .09 .12
Iowa triad:
Alle .65 .37–1.15 4.54 1.20–17.15 7.03 1.67–28.98 8.7 .003f .02
No anomaliesg .60 .33–1.10 4.61 1.20–17.76 7.72 1.80–32.83 9.2 .002 .03
CLO .48 .15–1.50 6.21 1.20–31.64 12.9 1.90–88.01 7.3 .007 .01
CPO .63 .26–1.55 6.95 1.48–31.76 11.1 1.95–60.70 8.3 .004 .04
CL/P .75 .39–1.41 3.33 .78–14.12 4.45 .94–21.43 3.8 .05 .13
DBS and Iowa triad:
Alle .70 .47–.97 2.23 1.20–3.71 3.17 1.59–6.13 9.5 .002 !.001
No anomaliesg .69 .45–.96 2.21 1.19–3.72 3.21 1.62–6.34 9.5 .002 !.001
CPO .60 .37–1.19 4.25 1.51–7.33 7.13 1.88–13.41 11.4 !.001 !.001
CL/P .79 .49–1.13 1.76 .91–3.17 2.23 1.08–4.81 3.7 .05 .03
a RR of GSTT1-null genotype in nonsmoking mothers.
b RR of GSTT1-null genotype in smoking mothers.
c RR of the interaction effect between GSTT1-null genotype and maternal cigarette smoking.
d Adjusted for vitamin and alcohol use.
e Includes data from all subjects with nonsyndromic OC.
f The combined P value by use of Fisher’s method is .0009, which remains significant after correction for multiple tests (see the
“Material and Methods” section).
g Includes data from subjects without other minor anomalies.
Table A6. ORs of Fetal GSTT1 Deletion and Maternal Smoking Effects
in OC
Population,
Fetal GSTT1
Genotypea, and
Maternal Smokingb
No. of OR
95% CICases Controls Total Effectc Value
Iowa:
:
Yes 19 9 28 ORge 2.10 .92–4.70
No 30 57 87 ORg .52 .32–.85
/:
Yes 63 54 117 ORe 1.16 .76–1.76
No 180 179 359 Reference
DBS:
-:
Yes 20 14 34 ORge 2.80 1.37–5.61
No 21 49 70 ORg .84 .48–1.46
/:
Yes 78 128 206 ORe 1.20 .84–1.70
No 131 257 388 Reference
Iowa and DBS:
:
Yes 39 23 62 ORge 2.38 1.39–4.01
No 51 106 157 ORg .67 .47–.97
/:
Yes 141 182 323 ORe 1.09 .83–1.41
No 311 436 747 Reference
NOTE.—Data from all subjects with OC are included.
a  Indicates GSTT1-null genotype;/ indicates not-null GSTT1 genotype
(either one or two copies of the wild alleles).
b Yes or no.
c ORge is the OR of the joint GSTT1 deletion and maternal smoking versus none;
ORg is OR of the GSTT1 deletion alone versus none; ORe is the OR of maternal
smoking alone versus none.
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Table A7. Gene-Gene Interactive Effects
Gene 1 Gene 2 x2 P
CYP1B1_snp2 MSX1_snp5 12.213 .002
NAT2_snp1 IRF6_snp3 11.02 .004
UGT1A7_snp2 NAT2_snp1 10.7 .005
CYP1B1_snp2 AHR_snp2 10.54 .005
GSTM1_snp1 MSX1_snp1 10.536 .005
EPHX_snp1 CYP1B1_snp2 10.41 .005
GSTP1_snp1 EPHX1_snp1 9.67 .008
EPHX1_snp2 AHR_snp2 9.52 .009
EPHX1_snp1 GSTP1_snp1 9.45 .009
CYP1A2 EPHX1_snp2 9.17 .010
GSTP4_snp1 GSTP1_snp2 9.13 .010
HIF1A EPHX1_snp2 9.04 .011
HIF1A MSX1_snp6 9.033 .011
HIF1A GSTM1_snp1 8.98 .011
CYP1B1_snp1 MSX1_snp3 8.745 .013
GSTM3 MSX1_snp1 7.989 .018
CYP1A2 IRF6_snp50 7.94 .019
AHR_snp2 UGT1A7_snp2 7.88 .019
EPHX1_snp1 IRF6_snp32 7.34 .025
SULT1A1 MSX1_snp3 7.128 .028
NAT2_snp2 GSTM3 7.08 .029
UGT1A7_snp1 GSTM_null 7.83 .020
NOTE.—Only results with are included.2x 1 7
Table A8. Summary of Markers with in Tests for Different Effects in the Sample Sets StudiedP ! .05
Population
Genes Gene-Smoking Interaction
Offspring Mother Offspring Mother
Iowa AhR_snp2, CYP1B1_snp1, CYP1A1, CYP1A2,
GSTP1_snp3, NAT2_snp2, and NQO1
CYP1A1, GSTM3, and NAT2_snp1 EPHX1_snp1, GSTP1_snp2, HIF1A,
UGT1A7_snp1, and GSTT1_del
EPHX1_snp1 and
UGT1A7_snp1
DCS CYP1A1, CYP1A2, GSTA4_SNP2,
GSTM1_snp1, and NAT2_snp2
EPHX1_snp1, GSTP1_snp3,
NAT2_snp1, and
UGT1A7_snp2
CYP1B1_snp2, CYP1A1,
EPHX1_snp2, GSTA4_snp1,
GSTA4_snp2, GSTP1_snp3,
GSTP1_snp1, and
UGT1A7_snp1
CYP2E1, GSTP1_snp3,
HIF1A, NAT2_snp2,
and UGT1A7_snp1
DBSa CYP1A1 NA GSTT1_del NA
NOTE.—SNPs showing statistical significance in more than one population are shown in bold.
a No maternal samples were available in the DBS sample set, so tests of maternal genotype or maternal genotype and smoking interaction effects were not applicable
(NA). Only 9 (shown in table 3) of the 25 markers were genotyped in Danish case control samples.
Web Resources
The URLs for data presented herein are as follows:
COGENE Project, http://hg.wustl.edu/COGENE/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for CYP1A1, EPHX1, GSTM1, GSTT1,
NAT2, AHR-ARNT, IRF6, MSX1, GSTP1, UGT1A7, CYP1A2,
CYP1B1, GSTA4, FGFR1, FGFR2, CYP2E1, NQO1, and HIF1A)
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